Log in

ASX:RVAREVA Medical Stock Price, Forecast & News

Today's Range N/A
50-Day Range N/A
52-Week Range N/A
Average Volume37,292 shs
Market Capitalization$70.52 million
P/E RatioN/A
Dividend YieldN/A
REVA Medical, Inc., a medical device company, focuses on the development and commercialization of polymer-based bioresorbable products for vascular applications. The company offers Fantom Encore, a bioresorbable vascular scaffold for the treatment of coronary artery disease; and MOTIV bioresorbable vascular scaffold for the treatment of below-the-knee peripheral artery disease. It sells Fantom Encore in Germany, Switzerland, Austria, the Netherlands, Belgium, Luxembourg, Italy, and Turkey. The company was formerly known as MD3, Inc. and changed its name to REVA Medical, Inc. in March 2002. REVA Medical, Inc. was founded in 1998 and is headquartered in San Diego, California.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 0.0Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

0.63 out of 5 stars

Industry, Sector and Symbol

Industry Medical Devices



Sales & Book Value

Annual Sales$265,000.00
Book ValueA($0.18) per share



Market Cap$70.52 million
Next Earnings DateN/A
OptionableNot Optionable

Receive RVA News and Ratings via Email

Sign-up to receive the latest news and ratings for RVA and its competitors with MarketBeat's FREE daily newsletter.

REVA Medical (ASX:RVA) Frequently Asked Questions

How were REVA Medical's earnings last quarter?

REVA Medical Inc (ASX:RVA) announced its quarterly earnings results on Tuesday, August, 7th. The company reported $0.61 earnings per share for the quarter. View REVA Medical's earnings history.

Has REVA Medical been receiving favorable news coverage?

Media coverage about RVA stock has been trending very positive on Monday, according to InfoTrie Sentiment. The research firm identifies negative and positive news coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. REVA Medical earned a coverage optimism score of 4.0 on InfoTrie's scale. They also assigned media coverage about the company a news buzz of 10.0 out of 10, meaning that recent news coverage is extremely likely to have an effect on the company's share price in the near future. View the latest news aboutREVA Medical.

Who are some of REVA Medical's key competitors?

Who are REVA Medical's key executives?

REVA Medical's management team includes the following people:
  • Ms. Regina E. Groves, CEO & Director (Age 61)
  • Mr. Robert B. Stockman, Co-Founder & Director (Age 65)
  • Mr. Jeffrey A. Anderson, Sr. VP of Clinical & Regulatory Affairs (Age 52)
  • Ms. Leigh F. Elkolli, CFO, Principal Accounting Officer, Corp. Sec. & Corp. Controller (Age 47)
  • Ms. Jessica Earley, VP of Operations & Product Devel.

What is REVA Medical's stock symbol?

REVA Medical trades on the ASX under the ticker symbol "RVA."

How big of a company is REVA Medical?

REVA Medical has a market capitalization of $0.00 and generates $265,000.00 in revenue each year.

What is REVA Medical's official website?

The official website for REVA Medical is www.teamreva.com.

How can I contact REVA Medical?

REVA Medical's mailing address is 5751 Copley Dr, SAN DIEGO, CA 92111-7911, United States. The company can be reached via phone at +1-858-9663000.

This page was last updated on 5/25/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.